Nitrosourea efficacy in high-grade glioma

A survival gain analysis summarizing 504 cohorts with 24193 patients

Johannes E A Wolff, Su Berrak, Susannah E. Koontz Webb, Ming Zhang

Research output: Contribution to journalArticle

40 Citations (Scopus)

Abstract

Even though past studies have suggested efficacy of nitrosourea drugs in patients with high-grade glioma and temozolomide has recently been shown significantly to be beneficial, no conclusive comparisons between these agents have been published. We performed a survival gain analysis of 364 studies describing 24,193 patients with high-grade glioma treated in 504 cohorts, and compared the effects of drugs. The most frequent diagnoses were glioblastoma multiforme (GBM) (72%) and anaplastic astrocytoma (22%). The mean overall survival (mOS) was 14.1 months. The outcome was influenced by several of the known prognostic factors including the histological grade, if the tumors were newly diagnosed or recurrent, the completeness of resection, patients' age, and gender. This information allowed the calculation of a predicted mOS for each cohort based on their prognostic factors independent of treatment. Survival gain to characterize the influence of treatment was subsequently defined and validated as the difference between the observed and the predicted mOS. In 62 CCNU-treated cohorts and 15 ACNU-treated cohorts the survival gain was 5.3 months and 8.9 months (P < 0.0005), respectively. No detectable survival gain for patients treated with various BCNU-containing regimens was found. Conclusion CCNU- and ACNU- containing regimens were superior to BCNU containing regiments.

Original languageEnglish (US)
Pages (from-to)57-63
Number of pages7
JournalJournal of Neuro-Oncology
Volume88
Issue number1
DOIs
StatePublished - May 2008
Externally publishedYes

Fingerprint

Survival Analysis
Glioma
Survival
Nimustine
Lomustine
Carmustine
temozolomide
Cohort Effect
Astrocytoma
Glioblastoma
Pharmaceutical Preparations
Therapeutics
Neoplasms

Keywords

  • 1-(2-Chloroethyl)-3-(2,6-dioxo-3-piperidyl)
  • Carmustine
  • Glioblastoma multiforme
  • Lomustine
  • Nimustine
  • Ranimustine
  • Survival gain

ASJC Scopus subject areas

  • Clinical Neurology
  • Cancer Research
  • Oncology
  • Neuroscience(all)

Cite this

Nitrosourea efficacy in high-grade glioma : A survival gain analysis summarizing 504 cohorts with 24193 patients. / Wolff, Johannes E A; Berrak, Su; Koontz Webb, Susannah E.; Zhang, Ming.

In: Journal of Neuro-Oncology, Vol. 88, No. 1, 05.2008, p. 57-63.

Research output: Contribution to journalArticle

Wolff, Johannes E A ; Berrak, Su ; Koontz Webb, Susannah E. ; Zhang, Ming. / Nitrosourea efficacy in high-grade glioma : A survival gain analysis summarizing 504 cohorts with 24193 patients. In: Journal of Neuro-Oncology. 2008 ; Vol. 88, No. 1. pp. 57-63.
@article{35beb1c33d28403dacd417ede1786c2f,
title = "Nitrosourea efficacy in high-grade glioma: A survival gain analysis summarizing 504 cohorts with 24193 patients",
abstract = "Even though past studies have suggested efficacy of nitrosourea drugs in patients with high-grade glioma and temozolomide has recently been shown significantly to be beneficial, no conclusive comparisons between these agents have been published. We performed a survival gain analysis of 364 studies describing 24,193 patients with high-grade glioma treated in 504 cohorts, and compared the effects of drugs. The most frequent diagnoses were glioblastoma multiforme (GBM) (72{\%}) and anaplastic astrocytoma (22{\%}). The mean overall survival (mOS) was 14.1 months. The outcome was influenced by several of the known prognostic factors including the histological grade, if the tumors were newly diagnosed or recurrent, the completeness of resection, patients' age, and gender. This information allowed the calculation of a predicted mOS for each cohort based on their prognostic factors independent of treatment. Survival gain to characterize the influence of treatment was subsequently defined and validated as the difference between the observed and the predicted mOS. In 62 CCNU-treated cohorts and 15 ACNU-treated cohorts the survival gain was 5.3 months and 8.9 months (P < 0.0005), respectively. No detectable survival gain for patients treated with various BCNU-containing regimens was found. Conclusion CCNU- and ACNU- containing regimens were superior to BCNU containing regiments.",
keywords = "1-(2-Chloroethyl)-3-(2,6-dioxo-3-piperidyl), Carmustine, Glioblastoma multiforme, Lomustine, Nimustine, Ranimustine, Survival gain",
author = "Wolff, {Johannes E A} and Su Berrak and {Koontz Webb}, {Susannah E.} and Ming Zhang",
year = "2008",
month = "5",
doi = "10.1007/s11060-008-9533-5",
language = "English (US)",
volume = "88",
pages = "57--63",
journal = "Journal of Neuro-Oncology",
issn = "0167-594X",
publisher = "Kluwer Academic Publishers",
number = "1",

}

TY - JOUR

T1 - Nitrosourea efficacy in high-grade glioma

T2 - A survival gain analysis summarizing 504 cohorts with 24193 patients

AU - Wolff, Johannes E A

AU - Berrak, Su

AU - Koontz Webb, Susannah E.

AU - Zhang, Ming

PY - 2008/5

Y1 - 2008/5

N2 - Even though past studies have suggested efficacy of nitrosourea drugs in patients with high-grade glioma and temozolomide has recently been shown significantly to be beneficial, no conclusive comparisons between these agents have been published. We performed a survival gain analysis of 364 studies describing 24,193 patients with high-grade glioma treated in 504 cohorts, and compared the effects of drugs. The most frequent diagnoses were glioblastoma multiforme (GBM) (72%) and anaplastic astrocytoma (22%). The mean overall survival (mOS) was 14.1 months. The outcome was influenced by several of the known prognostic factors including the histological grade, if the tumors were newly diagnosed or recurrent, the completeness of resection, patients' age, and gender. This information allowed the calculation of a predicted mOS for each cohort based on their prognostic factors independent of treatment. Survival gain to characterize the influence of treatment was subsequently defined and validated as the difference between the observed and the predicted mOS. In 62 CCNU-treated cohorts and 15 ACNU-treated cohorts the survival gain was 5.3 months and 8.9 months (P < 0.0005), respectively. No detectable survival gain for patients treated with various BCNU-containing regimens was found. Conclusion CCNU- and ACNU- containing regimens were superior to BCNU containing regiments.

AB - Even though past studies have suggested efficacy of nitrosourea drugs in patients with high-grade glioma and temozolomide has recently been shown significantly to be beneficial, no conclusive comparisons between these agents have been published. We performed a survival gain analysis of 364 studies describing 24,193 patients with high-grade glioma treated in 504 cohorts, and compared the effects of drugs. The most frequent diagnoses were glioblastoma multiforme (GBM) (72%) and anaplastic astrocytoma (22%). The mean overall survival (mOS) was 14.1 months. The outcome was influenced by several of the known prognostic factors including the histological grade, if the tumors were newly diagnosed or recurrent, the completeness of resection, patients' age, and gender. This information allowed the calculation of a predicted mOS for each cohort based on their prognostic factors independent of treatment. Survival gain to characterize the influence of treatment was subsequently defined and validated as the difference between the observed and the predicted mOS. In 62 CCNU-treated cohorts and 15 ACNU-treated cohorts the survival gain was 5.3 months and 8.9 months (P < 0.0005), respectively. No detectable survival gain for patients treated with various BCNU-containing regimens was found. Conclusion CCNU- and ACNU- containing regimens were superior to BCNU containing regiments.

KW - 1-(2-Chloroethyl)-3-(2,6-dioxo-3-piperidyl)

KW - Carmustine

KW - Glioblastoma multiforme

KW - Lomustine

KW - Nimustine

KW - Ranimustine

KW - Survival gain

UR - http://www.scopus.com/inward/record.url?scp=42349089115&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=42349089115&partnerID=8YFLogxK

U2 - 10.1007/s11060-008-9533-5

DO - 10.1007/s11060-008-9533-5

M3 - Article

VL - 88

SP - 57

EP - 63

JO - Journal of Neuro-Oncology

JF - Journal of Neuro-Oncology

SN - 0167-594X

IS - 1

ER -